PTCH2

2020 Market Spotlight: Basal Cell Carcinoma - ResearchAndMarkets.com

Retrieved on: 
Friday, April 17, 2020
Pharmaceutical, Health, Oncology, Branches of biology, RTT, Histopathology, Carcinoma, Biology, Basal-cell carcinoma, Hedgehog signaling pathway, Thymidylate synthase, PTCH2, Hedgehog pathway inhibitors

The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Basal Cell Carcinoma (2020)" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals.
  • The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, and Hedgehog signaling pathway.
  • Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis.

Global Basal Cell Carcinoma Market Spotlight 2019: Key Marketed and Pipeline Drugs, Epidemiology, Clinical Trials, Patents, Licensing and Acquisition Deals, Revenue Forecasts

Retrieved on: 
Wednesday, June 19, 2019
Branches of biology, Carcinoma, Histopathology, Biology, Basal-cell carcinoma, RTT, Neoplasms, Hedgehog signaling pathway, PTCH2, Hedgehog pathway inhibitors

This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Points: 
  • This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
    The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, and hedgehog signaling pathway.
  • The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
  • There have been five licensing and asset acquisition activities involving basal cell carcinoma drugs during 2014-19.
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.

Global Basal Cell Carcinoma Market Spotlight Report 2019 Featuring Sun Pharmaceutical, Novartis, Roche, & Valeant Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019
Health, Oncology, Pharmaceutical, Branches of biology, Carcinoma, Histopathology, Basal-cell carcinoma, RTT, Biology, Neoplasms, Hedgehog signaling pathway, PTCH2, Hedgehog pathway inhibitors

The "Market Spotlight: Basal Cell Carcinoma" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Basal Cell Carcinoma" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts
    The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, and hedgehog signaling pathway.
  • The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with two drugs in Phase III.
  • Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.